Evogene traded at 150.50 this Thursday September 10th, decreasing 4.30 or 2.78 percent since the previous trading session. Looking back, over the last four weeks, Evogene lost 27.40 percent. Over the last 12 months, its price fell by 63.65 percent. Looking ahead, we forecast Evogene to be priced at 145.82 by the end of this quarter and at 132.63 in one year, according to Trading Economics global macro models projections and analysts expectations.
Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.